The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AGIO | -26.16% | +3.67% | +0.72% | +30% |
| S&P | +12.65% | +91.73% | +13.89% | +299% |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.88M | 43.7% |
| Gross Profit | $9.83M | 43.8% |
| Gross Margin | 76.30% | 0.0% |
| Market Cap | $2.33B | -7.7% |
| Market Cap / Employee | $4.78M | 0.0% |
| Employees | 488 | 27.4% |
| Net Income | -$103.43M | -110.9% |
| EBITDA | -$115.50M | -13.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $92.71M | -63.5% |
| Accounts Receivable | $5.03M | 61.3% |
| Inventory | 32 | 21.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.53M | -40.4% |
| Short Term Debt | $17.99M | 10.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.26% | -73.4% |
| Return On Invested Capital | -21.96% | 19.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$89.71M | -6.0% |
| Operating Free Cash Flow | -$88.15M | -4.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 3.91 | 2.88 | 2.60 | 3.01 | - |
| Price to Book | 1.15 | 1.09 | 1.31 | 1.70 | 9.21% |
| Price to Sales | 51.46 | 45.46 | 47.14 | 52.10 | -34.03% |
| Price to Tangible Book Value | 1.15 | 1.09 | 1.31 | 1.70 | 9.21% |
| Enterprise Value to EBITDA | -8.42 | -8.00 | -8.24 | -12.34 | -24.21% |
| Return on Equity | 57.3% | 60.3% | 64.0% | -27.6% | -151.38% |
| Total Debt | $56.99M | $52.94M | $48.76M | $44.52M | -26.83% |
No podcast episodes available.
AGIO earnings call for the period ending September 30, 2021.
AGIO earnings call for the period ending June 30, 2021.
AGIO earnings call for the period ending March 31, 2021.
AGIO earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
